Anyeep closes nearly RMB 100M Series B to fuel growth in analytical instruments

Recently, Anyeep (Suzhou) Medical Technology Co., Ltd. ("Anyeep") announced the completion of a Series B financing round amounting to nearly RMB 100 million. This round was co-led by Huada Songhe and BioTrack Capital, with continued investment from existing shareholder Yuanbio Venture Capital. The investment from Hanon Group was also promptly finalized.

The proceeds will be primarily used to enhance the performance and production capacity of its product lineup, including triple quadrupole mass spectrometers, high-resolution mass spectrometers, and online mass spectrometers. The funding will also support efforts to deepen the application exploration and market penetration of mass spectrometry instruments across various fields such as scientific research, food & drug & environmental monitoring, chemical engineering, and the semiconductor industry.

Anyeep focuses on the R&D and manufacturing of high-end mass spectrometry instruments, offering a comprehensive portfolio that includes gas chromatography-mass spectrometry (GC-MS), liquid chromatography-mass spectrometry (LC-MS), ultra-high-resolution mass spectrometers, and other systems in benchtop, vehicle-mounted/portable, and online configurations suitable for diverse application scenarios. With performance and reliability on par with internationally advanced standards, Anyeep provides robust solutions for analytical and detection applications across both traditional and strategic emerging industries.

As China's demand for independent control over high-end scientific instruments and supply chain security becomes increasingly urgent, coupled with the sustained release of demand for mass spectrometry analysis technologies from downstream strategic emerging industries, Anyeep is well-positioned to accelerate its breakthrough in the domestic substitution wave. Leveraging its diverse portfolio of high-performance mass spectrometry products and its comprehensive advantage of broad application coverage closely aligned with local incremental market needs, the company is poised to emerge as a significant force in China's high-end analytical instrumentation sector.